DiaSorin stock: Board schedules November 12, 2026 results for DiaSorin stock

Published on 10/20/2026 at 15:38 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

FY 2025 revenue reached EUR 1.20 billion. DiaSorin stock costs EUR 78.68 on October 20, 2026, up 2.34 percent versus the Frankfurt close.

Calendar and valuation

DiaSorin scheduled third-quarter results for November 12, 2026, in a calendar update dated October 5, 2026.
Fiscal year 2025 revenue reached EUR 1.20 billion and adjusted EBITDA was EUR 394.00 million.
DiaSorin stock costs EUR 78.68 at Lang & Schwarz on October 20, 2026 at 3:31 p.m. CEST, 2.34 percent above the Frankfurt close of October 19, 2026.

Techniker im Reinraum bedienen automatisierte Diagnostikgeräte in modernem Biotech-Labor — Modernes Diagnostiklabor von DiaSorin S.p.A., ISIN IT0003497168, zeigt präzise Biotech-Produktion und klinische Fertigung, Illustration mit AI erstellt.

DiaSorin (ISIN IT0003492391) is scheduled to approve its third-quarter 2026 results on November 12, 2026, according to a company calendar update published by FinancialFilings on October 5, 2026. The stock was trading at EUR 78.68 at Lang & Schwarz on October 20, 2026 at 3:31 p.m. CEST, up 2.34 percent versus the Frankfurt close of October 19, 2026 at EUR 76.88.

FY 2025 delivered EUR 1.20 billion

The reporting date follows a full-year 2025 in which DiaSorin reported revenue of EUR 1.20 billion, adjusted EBITDA of EUR 394.00 million, adjusted net profit of EUR 223.00 million and free cash flow of EUR 209.00 million. These figures are listed on the company's investor page, which also describes DiaSorin as a developer and manufacturer of immunodiagnostic and molecular diagnostic products.

The revenue base gives the November reporting date a clear measurement point. Third-quarter results will show whether the company's specialty diagnostics portfolio is translating into growth after the 2025 revenue total.

Price sits below the yearly high

On Euronext Milan, DiaSorin was quoted at EUR 78.48 on October 20, 2026 at 3:18 p.m. CEST. The same market snapshot showed a 52-week range of EUR 52.34 to EUR 79.72, placing the Lang & Schwarz price 1.30 percent below the upper boundary. Volume stood at 49,354 shares in that snapshot.

The price position is therefore firm but not a fresh yearly high. The Frankfurt close of EUR 76.88 provides the German trading comparison, while the current Lang & Schwarz quote is 2.34 percent higher.

What does the calendar change?

The November 12 date gives investors a defined checkpoint for revenue, profit and operating performance. The company said the conference call will take place on the same date, with the timing to be communicated separately.

Valuation has a second marker

A valuation model dated October 14, 2026 placed DiaSorin's calculated fair value at EUR 85.98, while the referenced price was EUR 78.48. The model therefore put the price 8.49 percent below fair value, but it explicitly described EUR 85.98 as a model calculation rather than an analyst target, according to Fair Value Calculator on October 14, 2026.

DiaSorin stock and the next report

The next company milestone is the November 12 approval of third-quarter results. Until then, the combination of a EUR 3.9 billion market capitalization, a price-to-earnings ratio of 24.48 and the 1.30 percent distance from the 52-week high frames the stock's valuation.

DiaSorin was trading at EUR 78.68 at Lang & Schwarz on October 20, 2026 at 3:31 p.m. CEST, 2.34 percent above the Frankfurt close of October 19, 2026 at EUR 76.88. The further course of trading is shown by the continuously updated real-time quote of DiaSorin stock.